Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Orchestra BioMed Holdings (NASDAQ:OBIO) and maintained a price target of $20.

August 11, 2023 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Orchestra BioMed Holdings' stock has been reiterated as a 'Buy' by Chardan Capital, with a maintained price target of $20.
The reiteration of a 'Buy' rating by a financial analyst usually indicates a positive outlook for the company's stock. The maintained price target of $20 also suggests that the analyst believes the stock is undervalued at its current price, which could lead to an increase in demand and subsequently, a rise in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100